Monitoring circulating tumor cells in cancer vaccine trials

J. D. Gates; L. C. Benavides; A. Stojadinovic; E. A. Mittendorf; J. P. Holmes; M. G. Carmichael; S. McCall; A. L. Milford; G. A. Merrill; S. Ponniah; George E. Peoples

doi:10.4161/hv.4.5.6115

Monitoring circulating tumor cells in cancer vaccine trials

J. D. Gates, L. C. Benavides, A. Stojadinovic, E. A. Mittendorf, J. P. Holmes, M. G. Carmichael, S. McCall, A. L. Milford, G. A. Merrill, S. Ponniah, George E. Peoples

Surgical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

10 Scopus citations

Abstract

The presence of circulating tumor cells (CTC) from various cancers has provided a wealth of information and possibilities. As the role of CTC detection in the treatment assessment of metastatic breast cancer becomes standard, there is interest in applying this tool in cancer vaccine development and clinical trial monitoring. Since we lack a proven immunologic assay that correlates with clinical response, CTC detection, quantification and phenotypic characterization may be a useful surrogate for clinical outcome. The Cancer Vaccine Development Program is involved in the development of HER2/neu peptide based vaccine development for the prevention of recurrence in HER2/neu expressing cancers like breast cancer. The CellSearch System (Veridex, LLC, Warren, NJ) has been used by our lab in conjunction with in vivo and/or in vitro immunologic measurements to define a monitoring tool that could predict clinical response. Once validated, this assay could significantly shorten clinical trials and lead to more efficient assessment of potentially promising cancer vaccines.

Original language	English (US)
Pages (from-to)	389-392
Number of pages	4
Journal	Human Vaccines
Volume	4
Issue number	5
DOIs	https://doi.org/10.4161/hv.4.5.6115
State	Published - 2008

Keywords

Cancer
Circulating tumor cells
HER2/neu
Immunotherapy
Vaccine

ASJC Scopus subject areas

Immunology
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.4161/hv.4.5.6115

Cite this

@article{22ad44743b8b45f09a9885e8311840d2,

title = "Monitoring circulating tumor cells in cancer vaccine trials",

abstract = "The presence of circulating tumor cells (CTC) from various cancers has provided a wealth of information and possibilities. As the role of CTC detection in the treatment assessment of metastatic breast cancer becomes standard, there is interest in applying this tool in cancer vaccine development and clinical trial monitoring. Since we lack a proven immunologic assay that correlates with clinical response, CTC detection, quantification and phenotypic characterization may be a useful surrogate for clinical outcome. The Cancer Vaccine Development Program is involved in the development of HER2/neu peptide based vaccine development for the prevention of recurrence in HER2/neu expressing cancers like breast cancer. The CellSearch System (Veridex, LLC, Warren, NJ) has been used by our lab in conjunction with in vivo and/or in vitro immunologic measurements to define a monitoring tool that could predict clinical response. Once validated, this assay could significantly shorten clinical trials and lead to more efficient assessment of potentially promising cancer vaccines.",

keywords = "Cancer, Circulating tumor cells, HER2/neu, Immunotherapy, Vaccine",

author = "Gates, {J. D.} and Benavides, {L. C.} and A. Stojadinovic and Mittendorf, {E. A.} and Holmes, {J. P.} and Carmichael, {M. G.} and S. McCall and Milford, {A. L.} and Merrill, {G. A.} and S. Ponniah and Peoples, {George E.}",

note = "Funding Information: Supported by the United States Military Cancer Institute,",

year = "2008",

doi = "10.4161/hv.4.5.6115",

language = "English (US)",

volume = "4",

pages = "389--392",

journal = "Human Vaccines",

issn = "1554-8600",

publisher = "Landes Bioscience",

number = "5",

}

TY - JOUR

T1 - Monitoring circulating tumor cells in cancer vaccine trials

AU - Gates, J. D.

AU - Benavides, L. C.

AU - Stojadinovic, A.

AU - Mittendorf, E. A.

AU - Holmes, J. P.

AU - Carmichael, M. G.

AU - McCall, S.

AU - Milford, A. L.

AU - Merrill, G. A.

AU - Ponniah, S.

AU - Peoples, George E.

N1 - Funding Information: Supported by the United States Military Cancer Institute,

PY - 2008

Y1 - 2008

N2 - The presence of circulating tumor cells (CTC) from various cancers has provided a wealth of information and possibilities. As the role of CTC detection in the treatment assessment of metastatic breast cancer becomes standard, there is interest in applying this tool in cancer vaccine development and clinical trial monitoring. Since we lack a proven immunologic assay that correlates with clinical response, CTC detection, quantification and phenotypic characterization may be a useful surrogate for clinical outcome. The Cancer Vaccine Development Program is involved in the development of HER2/neu peptide based vaccine development for the prevention of recurrence in HER2/neu expressing cancers like breast cancer. The CellSearch System (Veridex, LLC, Warren, NJ) has been used by our lab in conjunction with in vivo and/or in vitro immunologic measurements to define a monitoring tool that could predict clinical response. Once validated, this assay could significantly shorten clinical trials and lead to more efficient assessment of potentially promising cancer vaccines.

AB - The presence of circulating tumor cells (CTC) from various cancers has provided a wealth of information and possibilities. As the role of CTC detection in the treatment assessment of metastatic breast cancer becomes standard, there is interest in applying this tool in cancer vaccine development and clinical trial monitoring. Since we lack a proven immunologic assay that correlates with clinical response, CTC detection, quantification and phenotypic characterization may be a useful surrogate for clinical outcome. The Cancer Vaccine Development Program is involved in the development of HER2/neu peptide based vaccine development for the prevention of recurrence in HER2/neu expressing cancers like breast cancer. The CellSearch System (Veridex, LLC, Warren, NJ) has been used by our lab in conjunction with in vivo and/or in vitro immunologic measurements to define a monitoring tool that could predict clinical response. Once validated, this assay could significantly shorten clinical trials and lead to more efficient assessment of potentially promising cancer vaccines.

KW - Cancer

KW - Circulating tumor cells

KW - HER2/neu

KW - Immunotherapy

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=54949097358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54949097358&partnerID=8YFLogxK

U2 - 10.4161/hv.4.5.6115

DO - 10.4161/hv.4.5.6115

M3 - Comment/debate

C2 - 18437056

AN - SCOPUS:54949097358

SN - 1554-8600

VL - 4

SP - 389

EP - 392

JO - Human Vaccines

JF - Human Vaccines

IS - 5

ER -

Monitoring circulating tumor cells in cancer vaccine trials

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this